International Flavors & Fragrances
IFF
$84.11
+0.23%
International Flavors & Fragrances Inc. (IFF) is the world's largest specialty ingredients producer, manufacturing proprietary flavor, fragrance, food ingredient, and health & bioscience formulations for the food, beverage, personal care, household goods, and pharmaceutical industries, with roughly 21,500 employees and a market capitalization near $17.3 billion. The company holds a leadership position across three core franchises — Taste, Scent, and Health & Biosciences — each contributing roughly 25-30% of profits, giving it a diversified, formulation-driven moat built on long customer relationships and high switching costs. The current investor narrative centers on a portfolio simplification story: management is divesting the lower-margin Food Ingredients business (a deal expected to close in 2027) to refocus on higher-growth, higher-margin taste, scent, and bioscience assets, while simultaneously working to restore earnings quality after a string of goodwill impairments and restructuring charges. Debate among investors hinges on whether the remaining core can deliver durable mid-single-digit organic growth and margin recovery, with the stock having rebounded sharply over the past year even as recent quarterly results showed a steep revenue decline tied to divestitures and soft demand.…
IFF
International Flavors & Fragrances
$84.11
Related headlines
Investment Opinion: Should I buy IFF Today?
Based on the synthesis of analyst recommendations, valuation metrics, and growth prospects, IFF warrants a Hold rating with a positive bias. The analyst consensus is Buy with an average target price of $96.29, implying a 16.8% upside from the current price of $82.42. However, the company's current lack of profitability and the risks associated with its portfolio transformation suggest that caution is warranted. The core thesis is that IFF is a turnaround story with significant potential, but execution risks remain high.
The supporting evidence for a Hold rating includes several factors. First, the stock trades at a forward PE of 20.8, which is reasonable for a market leader with a strong moat. Second, the price-to-book ratio of 1.22 is near historical lows, suggesting undervaluation. Third, the company generates robust free cash flow of $536 million, which can be used to reduce debt and invest in growth. Fourth, the gross margin improved to 43.65% in Q2 2026 from 37.26% a year earlier, indicating progress in margin recovery. However, the negative net margin and revenue decline are offsetting factors. The estimated EPS for the next fiscal year is $4.86, which would put the forward PE at 16.9, but this is based on analyst estimates that may be optimistic.
The biggest risks that could invalidate the thesis include a failure to achieve the projected margin improvements, a slower-than-expected recovery in demand, and execution missteps in the divestiture process. The rating would upgrade to Buy if the company demonstrates sustained revenue growth and positive net income for two consecutive quarters, or if the stock price falls below $70, providing a more attractive entry point. Conversely, a downgrade to Sell would occur if revenue growth remains negative and net margins fail to improve, or if the divestiture is delayed or unfavorable terms. Relative to its history and peers, IFF appears undervalued on a price-to-book basis but fairly valued on a forward PE basis. The stock is not a screaming buy, but it offers a balanced risk-reward for patient investors.
Sign up to view all
IFF 12-Month Price Forecast
The 12-month outlook for IFF is balanced, with a neutral stance. The company's strong free cash flow and undervaluation on a price-to-book basis are offset by negative profitability and revenue headwinds. The analyst consensus target of $96.29 implies a 16.8% upside, but the high short interest and recent underperformance suggest caution. The base case, with a 55% probability, targets $90-$96, assuming steady progress on the turnaround. The bull case (25% probability) targets $96-$105 on successful execution, while the bear case (20% probability) targets $59-$76 on failure to improve margins. I would upgrade to bullish if the company reports two consecutive quarters of positive net income and revenue growth, and downgrade to bearish if revenue declines persist and margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $96.29 and implied upside of +14.5% versus the current price.
Average Target
$96.29
0 analysts
Implied Upside
+14.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$76 - $105
Analyst target range
Bulls vs Bears: IFF Investment Factors
The bull case for IFF rests on its successful portfolio transformation, strong free cash flow, and significant undervaluation relative to analyst targets and historical multiples. The bear case highlights the company's current lack of profitability, revenue headwinds from divestitures, and high short interest. While the bull points are supported by concrete data such as the 16.8% upside to analyst targets and improving gross margins, the bear points are equally compelling given the negative net margin and recent underperformance. The most critical tension is whether the divestiture of Food Ingredients will ultimately lead to higher margins and growth, or if it will leave a revenue void that the remaining segments cannot fill. The resolution of this tension will likely determine the stock's trajectory over the next 12 months.
Bullish
- Analyst consensus target implies 16.8% upside: The average analyst target price of $96.29 across 17 analysts represents a 16.8% premium to the current price of $82.42. The low target of $76.00 is only 7.8% below the current price, suggesting limited downside according to the analyst community. The recommendation mean of 1.75 (buy) reflects strong conviction.
- Portfolio simplification to boost margins: Management is divesting the lower-margin Food Ingredients business, with the deal expected to close in 2027. This should improve the company's overall margin profile, as the remaining Taste, Scent, and Health & Biosciences segments generate higher margins. Q2 2026 gross margin already improved to 43.65% from 37.26% in Q2 2025.
- Strong free cash flow generation: IFF generated $536 million in trailing twelve-month free cash flow, which provides ample liquidity to reduce debt and invest in growth initiatives. The current ratio of 1.42 indicates a healthy balance sheet with sufficient short-term liquidity. Debt-to-equity of 0.47 is manageable.
- Undervalued on price-to-book and PEG: The stock trades at a price-to-book ratio of 1.22, which is near historical lows and well below the specialty chemicals sector average. The PEG ratio of 0.18, based on forward earnings growth, suggests the stock is significantly undervalued relative to its growth potential. The forward PE of 20.8 is reasonable for a market leader.
Bearish
- Negative earnings and weak profitability: The company reported a trailing twelve-month EPS of -$0.02 and a net margin of -3.31%, reflecting recent losses. The return on equity is -2.55%, indicating that the company is not generating positive returns for shareholders on a trailing basis. This raises concerns about the sustainability of the turnaround.
- Steep revenue decline due to divestitures: Q2 2026 revenue fell 29.31% year-over-year to $1.954 billion, largely due to divestitures and soft demand. While the divestiture of Food Ingredients is strategic, the loss of revenue creates a growth gap that the remaining segments must fill. The estimated revenue for the next fiscal year is $8.52 billion, which is below the current annualized run rate.
- High leverage and interest burden: Although debt-to-equity is 0.47, the company carries significant debt, with interest expense of $46 million in Q2 2026 alone. The EV/EBITDA ratio of 29.93 is elevated, suggesting that the company's enterprise value is high relative to its cash earnings. This limits financial flexibility and increases risk if earnings disappoint.
- Short interest is elevated: The short ratio of 11.33 indicates that it would take over 11 days of average trading volume to cover all short positions. This high level of short interest suggests that many investors are betting against the stock, potentially due to concerns about the company's ability to execute its turnaround strategy.
IFF Technical Analysis
Beta
0.93
0.93x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$59-$89
Price range past year
Annual Return
+37.8%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +0.9% |
| 3m | +7.1% | +3.4% |
| 6m | +16.0% | +14.4% |
| 1y | +37.8% | +16.2% |
| ytd | +23.6% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
Quarterly Revenue
$2.0B
2026-06
Revenue YoY Growth
-29.3%
YoY Comparison
Gross Margin
43.6%
Latest Quarter
Free Cash Flow
$536000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~181x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for IFF are significant. The company reported a trailing twelve-month EPS of -$0.02 and a net margin of -3.31%, indicating that it is currently unprofitable. Although Q2 2026 showed a positive net income of $50 million, the sustainability of this profitability is uncertain given the 29.31% year-over-year revenue decline. The company's debt-to-equity ratio of 0.47 is manageable, but interest expense of $46 million in Q2 2026 consumes a substantial portion of operating income. Additionally, the divestiture of the Food Ingredients business, expected to close in 2027, will remove a significant revenue stream, and there is no guarantee that the remaining segments will grow fast enough to offset the loss. The company's return on equity is -2.55%, reflecting poor capital efficiency.
Market and competitive risks are also prominent. IFF operates in the specialty chemicals industry, which is subject to economic cycles and competitive pressures. The stock has a beta of 0.953, meaning it is slightly less volatile than the overall market, but it is still exposed to macroeconomic downturns. The high short interest, with a short ratio of 11.33, indicates that many investors are bearish on the stock, which could lead to increased volatility. Furthermore, the company faces competition from other flavor and fragrance producers, and any loss of market share could hurt margins. Recent news highlights that IFF was included in a list of oversold S&P 500 stocks poised for a rebound, but this also underscores the stock's recent weakness. The relative strength over the past month is -5.79%, indicating underperformance versus the S&P 500.
The worst-case scenario for IFF would involve a failure to execute the turnaround strategy, leading to further revenue declines and margin compression. If the divestiture of Food Ingredients does not result in improved profitability, and if demand for the remaining segments weakens, the stock could retest its 52-week low of $59.14, which is 28.2% below the current price of $82.42. Additionally, the analyst low target of $76.00 represents a 7.8% downside, but in a severe scenario, the stock could fall to the 52-week low. The maximum drawdown over the past 180 days was -19.73%, indicating that the stock can experience significant declines. Investors could lose up to 28% from the current price in a worst-case scenario.
FAQ
The key risks include: 1) Financial risk: negative net margin of -3.31% and trailing EPS of -$0.02, with high debt (debt-to-equity 0.47) and interest expense of $46 million per quarter. 2) Execution risk: the divestiture of Food Ingredients may not yield expected margin improvements, and revenue already declined 29.31% year-over-year in Q2 2026. 3) Market risk: beta of 0.953 means the stock is sensitive to market downturns, and high short interest (short ratio 11.33) can amplify volatility. 4) Competitive risk: intense competition in specialty ingredients could pressure pricing and market share. These risks are ranked from highest to lowest severity, with financial and execution risks being the most immediate.
The 12-month forecast is based on three scenarios. The base case (55% probability) targets $90-$96, assuming steady margin improvement and revenue stabilization. The bull case (25% probability) targets $96-$105, driven by successful divestiture and accelerated growth. The bear case (20% probability) targets $59-$76, if the turnaround fails and revenue continues to decline. The most likely scenario is the base case, with the key assumption that IFF achieves positive net income and mid-single-digit organic growth by mid-2027. Analyst consensus target of $96.29 aligns with the base case.
IFF appears undervalued on several metrics. The price-to-book ratio of 1.22 is near historical lows, and the PEG ratio of 0.18 suggests the stock is cheap relative to expected growth. The forward PE of 20.8 is in line with the specialty chemicals sector, but the EV/EBITDA of 29.93 is elevated, reflecting high debt. The market is pricing in a successful turnaround, as the stock trades above the 52-week low of $59.14 but below the analyst average target of $96.29. If the company achieves its estimated EPS of $4.86, the forward PE would be 16.9, which is attractive. Overall, the stock is fairly valued to slightly undervalued, with upside contingent on execution.
IFF presents a balanced risk-reward proposition. The stock trades at $82.42, with analysts' average target of $96.29 implying a 16.8% upside. The company generates strong free cash flow of $536 million and trades at a low price-to-book ratio of 1.22, suggesting undervaluation. However, the trailing EPS is -$0.02 and net margin is -3.31%, indicating current unprofitability. The high short interest (short ratio 11.33) reflects bearish sentiment. For risk-tolerant investors with a 2-3 year horizon, IFF could be a good buy on dips, but it is not suitable for those seeking immediate income or low volatility.
IFF is more suitable for long-term investment (2-3 years) rather than short-term trading. The company is in the midst of a multi-year turnaround, with the Food Ingredients divestiture closing in 2027. The stock has a beta of 0.953, indicating moderate volatility, and pays a dividend yield of 2.37%, which appeals to income-oriented investors. However, the high short interest and recent price swings (max drawdown -19.73% over 180 days) make it risky for short-term traders. Earnings visibility is low due to restructuring charges and divestitures. A minimum holding period of 2 years is recommended to allow the turnaround to materialize.